JohnEGodwinMD

Oncology • Portland, OR

Hematologic Oncology

Physician

Join to view full profile

Dr. Godwin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Godwin's full profile

Already have an account?

Office
4805 Ne Glisan St
Ste 6n40
Portland, OR 97213
Phone+1 503-215-5696

Fax+1 217-545-4788

Summary

Dr. John Godwin is an oncologist in Portland, OR and is affiliated with multiple hospitals in the area, including Providence Milwaukie Hospital, Providence Newberg Medical Center, Providence Portland Medical Center, Providence St. Vincent Medical Center, and Providence Willamette Falls Medical Center. He received his medical degree from University of Alabama School of Medicine and has been in practice 43 years. He specializes in hematologic oncology and is experienced in acute myeloid leukemia and ovarian cancer. He has more than 100 publications and over 500 citings.

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1983 - 1985
Baylor College of MedicineResidency, Internal Medicine, 1979 - 1983
Baylor College of MedicineInternship, Transitional Year, 1978 - 1979
University of Alabama School of MedicineClass of 1978

Certifications & Licensure

OR State Medical License 2012 - 2025
IL State Medical License 1985 - 2014
AL State Medical License 1979 - 2012
NC State Medical License 1982 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACP) American College of Physicians, 2011
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

flt3L in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2000 Jul 01
Completed
Phase 3
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2003 Apr 01
Completed
Phase 2
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
Active, not recruiting
Phase 2
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08
Completed
Phase 1
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS Start of enrollment: 2016 Feb 01
Terminated
Phase 1, Phase 2
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Chenyu Lin, Anand A Patel, Dezheng Huo, Theodore Karrison, Koen van Besien
Blood Advances. 2024-11-26
1 citations
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Alain P Algazi, James Moon, Christopher D Lao, Bartosz Chmielowski, Kari L Kendra
Cancer. 2024-05-15
1 citations
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.
Megan Othus, Guillermo Garcia-Manero, John E Godwin, James K Weick, Frederick R Appelbaum
Haematologica. 2023-01-01

Journal Articles

Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials
Brent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature

Abstracts/Posters

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart¬ Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associat...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
The Hunt for a CRISPR Antidote Just Heated UpMay 21st, 2019